Sino Biopharmaceutic (SBMFF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 726,390 | 807,979 | 1,726,934 | N/A | N/A |
| Depreciation Amortization | 228,947 | 212,134 | 177,712 | N/A | N/A |
| Accounts receivable | -28,804 | 28,406 | -65,911 | N/A | N/A |
| Accounts payable and accrued liabilities | 29,921 | -13,155 | 132,361 | N/A | N/A |
| Other Working Capital | 37,867 | -40,321 | 36,763 | N/A | N/A |
| Other Operating Activity | -222,680 | -224,569 | -1,238,100 | 0 | 0 |
| Operating Cash Flow | $771,641 | $770,475 | $769,758 | $N/A | $N/A |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -322,190 | -112,757 | 77,359 | N/A | N/A |
| PPE Investments | -191,723 | -200,611 | -231,609 | N/A | N/A |
| Net Acquisitions | N/A | -7,134 | 181,554 | N/A | N/A |
| Purchase Of Investment | -608,109 | -24,941 | N/A | N/A | N/A |
| Sale Of Investment | 17,629 | 3,968 | N/A | N/A | N/A |
| Purchase Sale Intangibles | -52,742 | -36,583 | -19,196 | N/A | N/A |
| Other Investing Activity | -32,427 | -211,908 | -120,397 | 0 | 0 |
| Investing Cash Flow | $-1,136,821 | $-553,383 | $-93,093 | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 222,822 | 1,214,755 | 60,211 | N/A | N/A |
| Debt Issued | 822,079 | N/A | N/A | N/A | N/A |
| Common Stock Repurchased | -28,310 | -4,638 | -91,328 | N/A | N/A |
| Dividend Paid | -393,343 | -292,418 | -264,771 | N/A | N/A |
| Other Financing Activity | -299,660 | -512,418 | -33,170 | 0 | 0 |
| Financing Cash Flow | $323,589 | $405,281 | $-329,057 | $N/A | $N/A |
| Exchange Rate Effect | 40,574 | 13,754 | 36,637 | N/A | N/A |
| Beginning Cash Position | 1,540,462 | 902,209 | 557,868 | N/A | N/A |
| End Cash Position | 1,539,446 | 1,538,336 | 942,113 | N/A | N/A |
| Net Cash Flow | $-1,017 | $636,127 | $384,245 | $N/A | $N/A |
| Free Cash Flow | |||||
| Operating Cash Flow | 771,641 | 770,475 | 769,758 | N/A | N/A |
| Capital Expenditure | -206,380 | -209,741 | -234,202 | N/A | N/A |
| Free Cash Flow | 565,262 | 560,734 | 535,557 | 0 | 0 |